- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Turnstone Biologics Corp. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | Turnstone Biologics Corp. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | Turnstone Biologics Corp.: Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 11.10. | Turnstone Biologics To Cut 60% Jobs, Plans Restructuring; CFO Resigns; Stock Up | 1 | RTTNews | ||
| 11.10. | Turnstone Biologics announces strategic cuts and focus shift | 2 | Investing.com | ||
| 11.10. | Turnstone Biologics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| TURNSTONE BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 11.10. | Turnstone Biologics Corp.: Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway | 722 | GlobeNewswire (Europe) | Realigning resources to focus on clinical advancement of Selected TIL therapyReducing employee headcount by approximately 60%Streamlining operations with cash runway expected to extend into 2Q 2026... ► Artikel lesen | |
| 10.10. | Turnstone Biologics-Aktie stürzt auf 52-Wochen-Tief von 0,45 US-Dollar | 1 | Investing.com Deutsch | ||
| 10.10. | Turnstone Biologics stock plunges to 52-week low of $0.45 | 1 | Investing.com | ||
| 01.10. | Turnstone Biologics Corp. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.09. | Turnstone Biologics stock hits 52-week low at $0.58 amid sharp decline | 2 | Investing.com | ||
| 25.09. | Turnstone Biologics-Aktie erreicht 52-Wochen-Tief bei 0,58 US-Dollar | - | Investing.com Deutsch | ||
| 27.08. | Turnstone Biologics stock plunges to 52-week low of $0.72 | 2 | Investing.com | ||
| 15.08. | Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study | 1 | Benzinga.com | ||
| 15.08. | Why Is Turnstone Biologics (TSBX) Stock Down 38% Today? | 3 | InvestorPlace | ||
| 14.08. | Turnstone Biologics Corp. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Turnstone Biologics Corp. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.08. | Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights | 165 | GlobeNewswire (Europe) | Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations... ► Artikel lesen | |
| 14.08. | Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer | 122 | GlobeNewswire (Europe) | Overall response rate ("ORR") of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated... ► Artikel lesen | |
| 13.08. | Turnstone Biologics Corp. (TSBX): This Penny Stock is a 'Strong Buy' According to Analysts | 1 | Insider Monkey |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,200 | +20,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,361 | -1,63 % | Defence Therapeutics Inc.: Defence Announces Closing of Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,900 | 0,00 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,070 | +6,32 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,915 | -3,17 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2024 Financial Results and Operational Highlights | BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study
Upcoming... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,920 | -0,88 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,936 | -3,08 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,500 | +3,83 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
| VIR BIOTECHNOLOGY | 7,120 | +2,45 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,835 | +5,11 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,900 | +1,70 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 25,850 | +2,95 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,810 | +1,38 % | Bio-Path-Aktie stürzt auf 52-Wochen-Tief und erreicht 0,79 US-Dollar |
TURNSTONE BIOLOGICS CORP gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,49 % bei einem Aktienkurs von 0,481 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TURNSTONE BIOLOGICS CORP finden Sie auf Wallstreet Online.
